Showing results (1101-1110 of 2,811) with videos related to
Sort By:
Pageof 282
Expert Opinion on Drug Safety|March 12, 2024
A comprehensive analysis of liver safety across zibotentan oncology trials: knowledge of the past offers new perspectives on the presentAnna Fettiplace, Sherri Matis-Mitchell, Oleksandr Molodetskyi, et al.Expert Opinion on Drug Safety|March 14, 2024
Liver toxicity in oncology trials and beyond: a simplified concept for management of hepatocellular drug-induced liver injury in patients with abnormal baseline liver testsMichael Merz, Anna Fettiplace, John Marcinak, et al.Expert Opinion on Drug Safety|December 8, 2023
Priapism associated with anti-seizure medications: a pharmacovigilance study and a review of published casesNemanja Z Petrović, Ana V Pejčić, Ivan R MilovanovićExpert Opinion on Drug Safety|December 8, 2023
A systematic review and meta-analysis of tolerability, cardiac safety and efficacy of inclisiran for the therapy of hyperlipidemic patientsSiddhartha Dutta, Rima Shah, Shubha Singhal, et al.Expert Opinion on Drug Safety|November 8, 2023
Severe cutaneous adverse reactions due to antibiotics therapy: a pharmacovigilance analysis of FDA adverse event reporting system eventsLu Zhou, Jing Yang, Min Xiao, et al.Expert Opinion on Drug Safety|July 16, 2024
Hemorrhagic events associated with tacrolimus: a real-world pharmacovigilance studyHaolin Teng, Honglan Zhou, Faping LiExpert Opinion on Drug Safety|July 1, 2024
Comparative analysis of adverse events among intravesical drugs in bladder cancer: a real-world study on FAERS databaseYun Peng, Yuxuan Song, Yiqing Du, et al.Expert Opinion on Drug Safety|August 22, 2024
Assessment of the implementation of risk minimization measures for bosentan: a retrospective studyDaji Alyami, Ahmed H Abdelazeem, Adel A AlrwisanExpert Opinion on Drug Safety|August 22, 2024
A real-world pharmacovigilance study of cardiac adverse events induced by sugammadex in the FDA adverse event reporting systemXiao-Na Lin, You-Jie Zeng, Si Cao, et al.Expert Opinion on Drug Safety|September 6, 2024
Adverse events associated with Atogepant: a FAERS-based pharmacovigilance analysisYing Zhang, Shengzhu Sun, Yuming WangPageof 282